WO2017008773A1 - Formes cristallines d'acide obéticholique - Google Patents

Formes cristallines d'acide obéticholique Download PDF

Info

Publication number
WO2017008773A1
WO2017008773A1 PCT/CZ2016/000078 CZ2016000078W WO2017008773A1 WO 2017008773 A1 WO2017008773 A1 WO 2017008773A1 CZ 2016000078 W CZ2016000078 W CZ 2016000078W WO 2017008773 A1 WO2017008773 A1 WO 2017008773A1
Authority
WO
WIPO (PCT)
Prior art keywords
obeticholic acid
crystalline form
acid according
preparation
obeticholic
Prior art date
Application number
PCT/CZ2016/000078
Other languages
English (en)
Inventor
Iva OBADALOVA
Ondrej Dammer
Lukas KREJCIK
Jakub Hert
Original Assignee
Zentiva, K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.
Publication of WO2017008773A1 publication Critical patent/WO2017008773A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention relates to crystalline forms of obeticholic acid of formula I, with the systematic name (3a,5 ,6a,7a)-6-ethyl-3,7-dihydroxycholan-24-oic acid, a method of their preparation and use for the production of a dosage form.
  • These crystalline forms can be advantageously used to increase purity of obeticholic acid and also for the preparation of its amorphous form.
  • Obeticholic acid is a semi-synthetic bile acid analogue with an agonist effect upon the farnesoid X receptor (FXR). It is designed for the treatment of liver diseases, e.g. primary biliary cirrhosis (PBC), non-alcoholic steatohepatitis (NASH) or primary sclerosing cholangitis (PSC).
  • FXR farnesoid X receptor
  • Obeticholic acid was first mentioned in the patent application WO2002072598. It describes its isolation by means of column chromatography, which generally produced amorphous substances; however, the patent application does not disclose any more detailed data about the character of the product.
  • solid compounds can exist in various crystalline forms that are considered as polymorphs and hydrates/solvates, having different crystal units and thus different physicochemical properties such as the melting point, solubility, dissolution rate, as well as bioavailability.
  • solid- state analytic methods can be used, e.g. X-ray powder diffraction, solid-state NMR and Raman spectroscopy, as well as thermoanalytic methods.
  • This object of the present invention is crystalline forms of obeticholic acid.
  • the first of the forms, identified as 1-2, is a monohydrate and is characterized by an easy preparation process, high crystallinity and purification capability. Its significant advantage consists in the possibility of its re-drying to an amorphous form. Thus, there is no need to transform the crystalline form of obeticholic acid to a salt (e.g. sodium or ammonium) and subsequently prepare the amorphous form by precipitation.
  • a salt e.g. sodium or ammonium
  • the other form, identified as 1-3 exhibits high stability; the melting point of Form 1-3 is significantly higher than the melting points of Forms 1-2 or C.
  • Crystalline Form 1-2 of obeticholic acid exhibiting the following characteristic reflections in the X-ray powder pattern measured by CuKa radiation: 3.1; 6.2; 9.9; 12.4 and 16.7 ⁇ 0.2° 2-theta.
  • Crystalline Form 1-2 of obeticholic acid is characterized by the following further reflections in the X-ray powder pattern: 4.9; 8.9; 10.9 and 15.8 ⁇ 0.2° 2-theta.
  • Crystalline Form 1-2 of obeticholic acid is further characterized by the differential scanning calorimetry curve with the melting point at 80.9°C. In some embodiments, Crystalline Form 1-2 of obeticholic acid is in the form of monohydrate.
  • the invention further provides Crystalline Form 1-3 of obeticholic acid, exhibiting the following characteristic reflections in the X-ray powder pattern measured by CuKa radiation: 8.0; 10.6; 16.0 and 17.6 ⁇ 0.2° 2-theta. In some embodiments, Crystalline Form 1-3 of obeticholic acid is characterized by the following further reflections in the X-ray powder pattern: 10.0; 13.2 and 15.2 ⁇ 0.2° 2-theta.
  • the invention further provides the use of Crystalline Form 1-2 and/or Crystalline Form 1-3 of obeticholic acid for the preparation of an amorphous form of obeticholic acid.
  • the invention further provides a method for preparation of the amorphous form of obeticholic acid, comprising drying of Crystalline Form 1-2 in a vacuum drier at the temperature of 40°C or higher, preferably at a temperature in the range of 40 to 80°C.
  • Crystalline Form 1-2 of obeticholic acid is dried at the temperature of 40°C for at least 20 hours.
  • the invention further provides a method for preparation of the amorphous form of obeticholic acid, comprising:
  • step a) Crystalline Form 1-2 and/or Crystalline Form 1-3 of obeticholic acid is advantageously converted to the ammonium or sodium salt.
  • step b) an organic or inorganic acid is added, preferably hydrochloric or phosphoric acid.
  • the invention further provides the use of Crystalline Form 1-2 and or Crystalline Form 1-3 of obeticholic acid for the preparation of obeticholic acid with a chemical purity higher than 99.80% in accordance with HPLC.
  • the invention further provides the use of Crystalline Form 1-2 and/or Crystalline Form 1-3 for the preparation of a pharmaceutical composition.
  • the invention further provides a pharmaceutical composition containing Crystalline Form 1-2 and/or Crystalline Form 1-3 of obeticholic acid and at least one pharmaceutically acceptable excipient.
  • at least one pharmaceutically acceptable excipient is selected from the group comprising lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate and their combinations.
  • the pharmaceutical composition has the form of a tablet.
  • Fig. 1 XRPD pattern of Form 1-2 of obeticholic acid
  • Fig. 2 DSC record of Form 1-2 of obeticholic acid
  • Fig. 3 TGA record of Form 1-2 of obeticholic acid
  • Fig. 4 XRPD pattern of Form 1-3 of obeticholic acid
  • This invention provides two novel crystalline forms of obeticholic acid.
  • Form 1-2 exhibits a distinctly crystalline character.
  • the X-ray powder pattern of this salt is shown in Fig. 1. Its characteristic diffractions measured by CuKa radiation are 3.1; 6.2; 9.9; 12.4 and 16.7 ⁇ 0.2 °2-theta. Form 1-2 further exhibits the following characteristic reflections: 4.9; 8.9; 10.9 and 15.8 ⁇ 0.2 °2-theta. Diffraction peaks with a higher relative intensity than 15% are shown in Table 1.
  • DSC Differential scanning calorimetry
  • TGA thermogravimetric analysis
  • Form 1-2 of obeticholic acid contains 4.3 % of water, which corresponds to one molar equivalent (Fig. 3). Due to its high crystallinity, Form 1-2 is suitable not only for purification of crude obeticholic acid or for preparation of an amorphous form of obeticholic acid, but it is also directly usable in the dosage form.
  • Form 1-3 also exhibits a strongly crystalline character.
  • the X-ray powder pattern of this salt is shown in Fig. 4. Its characteristic diffractions measured by CuKa radiation are 8.0; 10.6; 16.0; and 17.6 ⁇ 0.2 °2-theta.
  • Form 1-3 further exhibits the following characteristic reflections: 10.0; 13.2 and 15.2 ⁇ 0.2 °2-theta. Diffraction peaks with a higher relative intensity than 15% are shown in Table 2.
  • Forms 1-2 and 1-3 can be advantageously used to increase the chemical purity of obeticholic acid. These forms crystallize well and remove impurities from obeticholic acid. Conversion of Form C to Form 1-2 increased the chemical purity from 99.10% (starting Form C) to 99.61% (final Form 1-2). The recrystallization of Form 1-2 alone also increases the chemical purity from the initial 99.61% to the final 99.98% (HPLC). Purification of crude obeticholic acid (HPLC purity 97.59%) can be advantageously achieved by conducting recrystallization through Form 1-2 and in such a case the chemical purity of the final product rises to 99.83% (HPLC) during a single crystallization.
  • Form 1-3 does not exhibit such a high tendency to crystallize as Form 1-2.
  • conversion of Form C to Form 1-3 increased the chemical purity from 99.10% (starting Form C) to 99.48% (final Form 1-3).
  • the recrystallization of Form 1-3 alone increased the chemical purity from the initial 99.48% to the final 99.87% (HPLC).
  • Purification of crude obeticholic acid (HPLC purity 97.59%) can be advantageously achieved by conducting recrystallization through Form 1-3 and in such a case the chemical purity of the final product rose to 98.99% (HPLC) during a single crystallization.
  • Crystalline Form 1-2 can be advantageously used to prepare the amorphous form by mere drying in a vacuum drier, wherein at the temperature of 40°C already the content of the amorphous form starts to increase. Vacuum drying for at least 20 hours at 40°C provides a nearly complete amorphous form. If vacuum drying is carried out at a higher temperature, the drying time is reduced proportionally.
  • the amorphous form of obeticholic acid can also be prepared directly during the formulation process, e.g. by spray drying or in a fluid bed reactor.
  • All the prepared forms of obeticholic acid according to this invention can be used for the preparation of pharmaceutical compositions, especially solid dosage forms, e.g. tablets.
  • Such pharmaceutical compositions can contain at least one excipient from the group of fillers (e.g. lactose), binders (e.g. microcrystalline cellulose), disintegrants (e.g. sodium salt of croscarmellose), lubricants (e.g. magnesium stearate), surfactants, etc.
  • These tablets can be coated with common coatings, e.g. polyvinyl alcohol or polyethylene glycol.
  • the preparation of the novel Crystalline Forms 1-2 and 1-3 comprises the following steps: a) dissolution and/or dispersion of obeticholic acid in a solvent/s;
  • the dissolution or dispersion in the solvent or mixture of solvents can be carried out at a temperature in the range from 20°C to the boiling point of the solvents. Subsequently, the mixture is usually cooled down to a temperature of 0°C to 30°C, preferably to the range of 20°C to 25°C, and left to crystallize. The mixture can be seeded.
  • the solid product can be isolated either directly by filtration, or concentration of the mixture, or evaporation of the solvents may follow.
  • the solvents can be selected from a group of solvents of general formula ROH, RCN, RCOR or RCOOR wherein R can be a CI to C4 carbon chain, preferably ethyl acetate, isopropyl acetate, butyl acetate, acetonitrile or 2-butanone.
  • room temperature refers, for the purposes of the text below and above, to the temperature range from 22 to 26°C. Overview of analytic methods
  • the primary optical equipment programmable divergence slits with the irradiated area of the sample of 10 mm, 0.02 rad Soller slits and a 1 ⁇ 4° anti-diffusion slit were used.
  • an X'Celerator detector with maximum opening of the detection slot 0.02 rad, Soller slits and a 5.0 mm anti-diffusion slit were used.
  • the records of differential scanning calorimetr were measured using a Discovery DSC device made by TA Instruments.
  • the sample charge in a standard Al pot (40 ⁇ ) was between 4 and 5 mg and the heating rate was 5°C/min.
  • As the carrier gas 5.0 N 2 was used at the flow of 50 ml/min.
  • thermogravimetric analysis TGA 6 device made by the company Perkin Elmer.
  • the sample charge in a corundum pot was 10-21 mg and the heating rate was 10°C/min.
  • the temperature program that was used consists of 1 minute's stabilization at the temperature of 20°C and then of heating up to 300°C at the heating rate of 10°C/min.
  • As the carrier gas 4.0 N 2 was used at the flow of 20 ml/min.
  • Chemical purity was measured with the use of liquid chromatography (HPLC):
  • Obeticholic acid was prepared according to the procedure disclosed in the patent application WO2002072598.
  • the chemical purity of crude obeticholic acid prepared this way was 97.59 % (HPLC).
  • the 1H and I3 C NMR spectra confirmed the structure of obeticholic acid.
  • Obeticholic acid (1 g, 2.38 mmol, 99.10% HPLC) was dissolved in 3 ml of butyl acetate under moderate reflux. The clear solution was left to slowly cool down to the room temperature and subsequently left to crystallize at the room temperature for approximately 3 hours. The produced crystals were aspirated and dried in a vacuum drier at 25°C for 6 hours. 850 mg of Crystalline Form 1-2 of obeticholic acid was obtained at the chemical purity of 99.61% (HPLC)
  • Obeticholic acid (0.5 g, 1.19 mmol, 97.59% HPLC) was dissolved in 2 ml of acetonitrile under moderate reflux. The clear solution was left to slowly cool down to the room temperature, seeded and subsequently left to crystallize at the room temperature for 24 hours. The produced crystals were aspirated and dried in a vacuum drier at 40°C for 6 hours. 380 mg of Crystalline Form 1-3 of obeticholic acid was obtained at the chemical purity of 98.99% (HPLC).
  • Obeticholic acid (1.5 g, 3.56 mmol, 99.61% HPLC) was dissolved in 4.5 ml of butyl acetate under moderate reflux. The clear solution was left to slowly cool down to the room temperature and subsequently left to crystallize at the room temperature for approximately 3 hours. The produced crystals were aspirated and dried in a vacuum drier at 25°C for 6 hours. 1.38 g of Crystalline Form 1-2 of obeticholic acid was obtained at the chemical purity of 99.98% (HPLC).
  • Obeticholic acid (3.8 g, 9.03 mmol, 97.59% HPLC) was dissolved in 20 ml of butyl acetate under moderate reflux. The clear solution was left to slowly cool down to the room temperature and subsequently left to crystallize at the room temperature for approximately 3 hours. The produced crystals were aspirated and dried in a vacuum drier at 25°C for 25 hours. 2.2 g of Crystalline Form 1-2 of obeticholic acid was obtained at the chemical purity of 99.83% (HPLC). This Form 1-2 was further dried in a vacuum drier at 40°C for 48 hours, providing amorphous obeticholic acid.
  • Obeticholic acid (580 mg) was dissolved in a solution of 8.7 ml of water and 8.7 ml of a 50% solution of sodium hydroxide at 40°C. The obtained solution was slowly added to diluted hydrochloric acid (37%, 9.6 ml) with water (8.7 ml) at 40°C. The produced suspension was stirred at 40°C for 30 minutes and then cooled down to 10°C. The solid fraction was filtered and washed with water. After drying in a vacuum drier (40°C), 526 mg of amorphous obeticholic acid was obtained.
  • Obeticholic acid 500 mg was dissolved in a solution of 5 ml of water and 0.11 g of 30% ammonia. The obtained solution was maintained at the temperature of 30 - 40°C and 150 mg of phosphoric acid was slowly added. The produced suspension was stirred at 30 - 40°C and then cooled down to 20°C and filtered. The solid fraction was washed with water (3 x 1 ml) and dried in a vacuum drier (40°C). 440 mg of amorphous obeticholic acid was obtained.

Abstract

La présente invention concerne l'acide obéticholique qui est un analogue de l'acide semi-synthétique biliaire avec un effet agoniste sur le récepteur farnésoïde X (FXR). Il est conçu pour le traitement des maladies hépatiques, par exemple la cirrhose biliaire primaire (PBC), la stéatohépatite non alcoolique (NASH) ou la cholangite sclérosante primaire (PSC). La présente invention concerne les formes cristallines de l'acide obéticholique de formule I, avec le nom systémique d'acide (3α,5β,6α,7α)-6-éthyl-3,7-dihydroxycholan-24-oïque, un procédé pour sa préparation et son utilisation pour la production d'une forme dosifiée. Lesdites formes cristallines peuvent être avantageusement utilisées pour accroître la pureté de l'acide obéticholique et également pour la préparation de sa forme amorphe.
PCT/CZ2016/000078 2015-07-16 2016-07-18 Formes cristallines d'acide obéticholique WO2017008773A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZPV2015-504 2015-07-16
CZ2015-504A CZ2015504A3 (cs) 2015-07-16 2015-07-16 Krystalické formy obeticholové kyseliny

Publications (1)

Publication Number Publication Date
WO2017008773A1 true WO2017008773A1 (fr) 2017-01-19

Family

ID=56617962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2016/000078 WO2017008773A1 (fr) 2015-07-16 2016-07-18 Formes cristallines d'acide obéticholique

Country Status (2)

Country Link
CZ (1) CZ2015504A3 (fr)
WO (1) WO2017008773A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017137931A1 (fr) 2016-02-10 2017-08-17 Dr. Reddy’S Laboratories Limited Sel d'amine de l'acide obéticholique
WO2017170858A1 (fr) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 Préparation orale présentant une exceptionnelle aptitude à l'élution
WO2017167233A1 (fr) * 2016-03-31 2017-10-05 江苏恒瑞医药股份有限公司 Nouvelle forme cristalline d'acide obéticholique et son procédé de préparation
EP3248983A4 (fr) * 2014-12-30 2017-12-13 Crystal Pharmatech Co. Ltd. Forme cristalline a de l'acide obéticholique et son procédé de préparation
EP3293196A1 (fr) * 2016-09-09 2018-03-14 Hexal AG Procédé de purification d'acide obéticholique
WO2018211413A1 (fr) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Formes solides d'acide obéticholique et procédé de préparation associé
WO2018215002A1 (fr) 2017-05-26 2018-11-29 Zentiva, K.S. Formes amorphes de l'acide obéticholique
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
CN109535216A (zh) * 2017-09-22 2019-03-29 上海汇伦生命科技有限公司 一种无定型奥贝胆酸的制备方法及无定型奥贝胆酸
CN109655571A (zh) * 2019-01-08 2019-04-19 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的高效液相色谱分析方法
CN109806386A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Fxr激动剂与glp-1类似物的药物组合物和用途
WO2019106043A1 (fr) 2017-11-29 2019-06-06 Hexal Ag Composition pharmaceutique comprenant de l'acide obéticholique
WO2019047989A3 (fr) * 2017-09-05 2019-06-06 Zentiva, K.S. FORMES CRISTALLINES D'ACIDE (3α,5β,6α,7α)-6-ÉTHYL-3,7-DIHYDROXYCHOLAN-24-IQUE
CN110831602A (zh) * 2017-03-08 2020-02-21 英特塞普特医药品公司 奥贝胆酸的结晶形式
WO2020097167A1 (fr) * 2018-11-08 2020-05-14 Intercept Pharmaceuticals, Inc. Méthodes d'utilisation d'acide obéticholique

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109212044B (zh) * 2017-06-30 2021-11-26 南京济群医药科技股份有限公司 一种奥贝胆酸有关物质的检测方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072598A1 (fr) 2001-03-12 2002-09-19 Roberto Pellicciari Steroides comme agonistes de fxr
WO2006122977A2 (fr) 2005-05-19 2006-11-23 Erregierre S.P.A. Procede d'elaboration d'acide 3?(?)-7?(?)-dihydroxy-6?(?)-alkyle-5?-cholanique
US20090062526A1 (en) 2007-08-28 2009-03-05 Yu Donna D novel method of synthesizing alkylated bile acid derivatives
WO2013192097A1 (fr) 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Préparation, utilisations et formes solides d'acide obéticholique
WO2014085474A1 (fr) * 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Traitement d'une maladie pulmonaire
CN105175473A (zh) * 2015-08-19 2015-12-23 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN105541953A (zh) * 2016-03-15 2016-05-04 成都市新功生物科技有限公司 一种高纯度奥贝胆酸的重结晶纯化方法
WO2016079517A1 (fr) * 2014-11-19 2016-05-26 Dextra Laboratories Limited Stéroïdes 6-alkyl-7-hydroxy-4-en-3-one utilisés en tant qu'intermédiaires pour la production de modulateurs de fxr stéroïdiens
WO2016107575A1 (fr) * 2014-12-30 2016-07-07 苏州晶云药物科技有限公司 Forme cristalline a de l'acide obéticholique et son procédé de préparation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072598A1 (fr) 2001-03-12 2002-09-19 Roberto Pellicciari Steroides comme agonistes de fxr
WO2006122977A2 (fr) 2005-05-19 2006-11-23 Erregierre S.P.A. Procede d'elaboration d'acide 3?(?)-7?(?)-dihydroxy-6?(?)-alkyle-5?-cholanique
US20090062526A1 (en) 2007-08-28 2009-03-05 Yu Donna D novel method of synthesizing alkylated bile acid derivatives
WO2013192097A1 (fr) 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Préparation, utilisations et formes solides d'acide obéticholique
WO2014085474A1 (fr) * 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Traitement d'une maladie pulmonaire
WO2016079517A1 (fr) * 2014-11-19 2016-05-26 Dextra Laboratories Limited Stéroïdes 6-alkyl-7-hydroxy-4-en-3-one utilisés en tant qu'intermédiaires pour la production de modulateurs de fxr stéroïdiens
WO2016107575A1 (fr) * 2014-12-30 2016-07-07 苏州晶云药物科技有限公司 Forme cristalline a de l'acide obéticholique et son procédé de préparation
CN105175473A (zh) * 2015-08-19 2015-12-23 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN105541953A (zh) * 2016-03-15 2016-05-04 成都市新功生物科技有限公司 一种高纯度奥贝胆酸的重结晶纯化方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ZHOU, YUEGUANG ET AL: "Obeticholic acid crystal form I, its preparation method and the pharmaceutical composition", XP002762400, retrieved from STN Database accession no. 2015:2080440 *
DATABASE WPI Week 201646, Derwent World Patents Index; AN 2016-28903L, XP002762402 *
DATABASE WPI Week 201648, Derwent World Patents Index; AN 2016-414317, XP002762401 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3248983A4 (fr) * 2014-12-30 2017-12-13 Crystal Pharmatech Co. Ltd. Forme cristalline a de l'acide obéticholique et son procédé de préparation
WO2017137931A1 (fr) 2016-02-10 2017-08-17 Dr. Reddy’S Laboratories Limited Sel d'amine de l'acide obéticholique
WO2017170858A1 (fr) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 Préparation orale présentant une exceptionnelle aptitude à l'élution
WO2017167233A1 (fr) * 2016-03-31 2017-10-05 江苏恒瑞医药股份有限公司 Nouvelle forme cristalline d'acide obéticholique et son procédé de préparation
US11413295B2 (en) 2016-03-31 2022-08-16 Intercept Pharmaceuticals, Inc. Oral preparation of obeticholic acid
US11161871B2 (en) 2016-03-31 2021-11-02 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of obeticholic acid and preparation method therefor
EP3293196A1 (fr) * 2016-09-09 2018-03-14 Hexal AG Procédé de purification d'acide obéticholique
WO2018165269A3 (fr) * 2017-03-08 2020-03-26 Intercept Pharmaceuticals, Inc Formes cristallines de l'acide obéticholique
CN110831602A (zh) * 2017-03-08 2020-02-21 英特塞普特医药品公司 奥贝胆酸的结晶形式
WO2018211413A1 (fr) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Formes solides d'acide obéticholique et procédé de préparation associé
WO2018215002A1 (fr) 2017-05-26 2018-11-29 Zentiva, K.S. Formes amorphes de l'acide obéticholique
WO2019047989A3 (fr) * 2017-09-05 2019-06-06 Zentiva, K.S. FORMES CRISTALLINES D'ACIDE (3α,5β,6α,7α)-6-ÉTHYL-3,7-DIHYDROXYCHOLAN-24-IQUE
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
CN109535216A (zh) * 2017-09-22 2019-03-29 上海汇伦生命科技有限公司 一种无定型奥贝胆酸的制备方法及无定型奥贝胆酸
CN109535216B (zh) * 2017-09-22 2022-09-16 上海汇伦医药股份有限公司 一种无定型奥贝胆酸的制备方法及无定型奥贝胆酸
CN109806386A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Fxr激动剂与glp-1类似物的药物组合物和用途
WO2019106043A1 (fr) 2017-11-29 2019-06-06 Hexal Ag Composition pharmaceutique comprenant de l'acide obéticholique
WO2020097167A1 (fr) * 2018-11-08 2020-05-14 Intercept Pharmaceuticals, Inc. Méthodes d'utilisation d'acide obéticholique
CN109655571A (zh) * 2019-01-08 2019-04-19 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的高效液相色谱分析方法

Also Published As

Publication number Publication date
CZ2015504A3 (cs) 2017-01-25

Similar Documents

Publication Publication Date Title
WO2017008773A1 (fr) Formes cristallines d'acide obéticholique
EP3248983B1 (fr) Forme cristalline a de l'acide obéticholique et son procédé de préparation
EP3243824A1 (fr) Les formes solides de la base libre de l'ibrutinib
EP3256474B1 (fr) Sel de sulfate ibrutinib
US20090076272A1 (en) Polymorphs of eszopiclone malate
WO2016131431A1 (fr) Formes solides d'empagliflozine
JP2019509308A (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミン塩の新規な結晶形
WO2016127963A1 (fr) Formes solides de sels de palbociclib
WO2018046028A1 (fr) Formes à l'état solide d'éluxadoline
WO2010010454A2 (fr) Formes cristallines d’un sel de malate de 2-indolinone à substitution 3-pyrrole
WO2016058564A1 (fr) Sels de bédaquiline
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
EP3328848A1 (fr) Formes solides de ceritinib base libre
US20200407382A1 (en) Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
WO2017186197A1 (fr) Sels de lenvatinib
EP3473623B1 (fr) Formes cristallines de nbi-98854, procédé de préparation s'y rapportant et utilisation associée
EP3256477A1 (fr) Formes solides des sels de dolutegravir et procédé de préparation associé
US10577340B1 (en) Beraprost-314d crystals and methods for preparation thereof
CZ2016222A3 (cs) Pevné formy solí obeticholové kyseliny
EP3372592A1 (fr) Formes solides de sels d'amines de lesinurad
CA2944150A1 (fr) Formes polymorphes et co-cristaux d'un inhibiteur de c-met
WO2019047989A2 (fr) FORMES CRISTALLINES D'ACIDE (3α,5β,6α,7α)-6-ÉTHYL-3,7-DIHYDROXYCHOLAN-24-IQUE
WO2015170340A2 (fr) Nouveaux polymorphes de chlorhydrate de sitagliptine, procédés de préparation et composition pharmaceutique de ceux-ci
WO2023042214A1 (fr) Formes à l'état solide de rélugolix
KR20200068667A (ko) 고체 형태의 스테모스피로닌 및 이의 염

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16750087

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16750087

Country of ref document: EP

Kind code of ref document: A1